Abstract
This study was conducted to compare the efficacy of intravenous diphenhydramine with dihydroergotamine mesylate (DHE-45; Novartis International AG, Switzerland) in the treatment of severe, refractory, migraine headache. A retrospective review was conducted to include eighty randomly chosen patients who were admitted to the Michigan Head Pain & Neurological Institute’s inpatient program at Chelsea Community Hospital. Patients had received nine doses of diphenhydramine or nine doses of DHE-45 during a 3-day period. Patients receiving DHE-45 also received metoclopramide (Reglan; AH Robins Company, Inc., Richmond, VA) as prophylaxis for nausea. Demographics, headache diagnosis, psychiatric discharge diagnoses, abortive medications, and adverse events were recorded and assessed.
Similar content being viewed by others
References and Recommended Reading
Saper, Joel R, Hamel R, et al.: Handbook of Headache Management: A Practical Guide to Diagnosis and Treatment of Head, Neck, and Facial Pain. Baltimore: Lippincott Williams & Wilkins; 1999. This handbook is a great review of the pathophysiology of migraine. The authors review the various neurotransmitters involved in migraine pathogenesis and practical treatment guidelines for nonheadache clinicians.
Raskin N, Callahan M: A controlled study of DHE-45 in the treatment of acute migraine headache. Headache 1986, 26:168–171.
Young WB: Appropriate use of ergotamine tartrate and DHE-45 in the treatment of migraine: current perspectives. Headache 1997, 37(suppl 1):S42-S45.
Swidan S, Hamel R, Saper J, et al.: The efficacy of IV diphenhydramine vs. dihydroergotamine, ketorolac, chlorpromazine, and droperidol in the treatment of refractory daily chronic headache [Abstract]. Neurology 1999, 52(suppl 2):A255-A256.
Mansfield LE: The role of antihistamine therapy in vascular headaches. J Allergy Clin Immunol 1990, 86:673–676. Various studies have linked the role of histamine to cluster and migraine headaches. Thus far, it is unclear which neurotransmitter interplay seems more critical in provoking headaches in prone patients. Recent studies demonstrated that various histamine receptors exist and various receptor conformations may be a useful guide to future drug development targeting these receptors. Further studies of H3 histamine receptors, which indicate that H3 agonists offer promise as prophylactic agents for people who suffer from headaches are warranted.
Anthony M, Lord GD, Lance JW: Controlled trials of cimetidine in migraine and cluster headache. Headache 1978, 18:261–264.
Somerville BW: Treatment of migraine attacks with an analgesic combination (mersyndol). Med J Aust 1976, 1:865–866.
Lane PL, McLellan BA, Baggoley CJ: Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989, 18:360–365.
Thomsen LL, Olesen J: A pivotal role of nitric oxide in migraine pain. Ann NY Acad Sci 1997, 835:363–372.
Thomsen LL: Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia 1997, 17:873–893.
Olesen J, Thomsen LL, Lassen LH, et al.: The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 1995, 15:94–100.
Lassen LH, Thomsen LL, Kruuse C, et al.: Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Eur J Clin Pharmacol 1996, 49:335–339.
Welch KM: Pathogenesis of migraine. Sem Neurol 1997, 17:335–341. This article reviews the complex interplay of the various neurotransmitters for the mechanism of headache. Models of aura mechanisms include transient cerebral ischemia and spreading depression also are reviewed. It has been shown by various publications thus far that migraine attacks are caused by various malfunctions that involve the trigeminovascular system and brain stem. The trigger of a migraine attack depends on various factors such as threshold of brain excitability. Mitochondrial disorder, magnesium deficiency, and abnormality of presynaptic calcium channels.
Ottosson A, Edvinsson L: Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide and effect of sumatriptan. In Headache Pathogenesis: Monoamines, Neuropeptides, Purines, and Nitric Oxide. Edited by Olesen J, Edvinsson L. Philadelphia: Lippincott-Raven; 1997:167–171.
Heatley RV, Denburg JA, Bayer N, et al.: Increased plasma histamine levels in migraine patients. Clin Allergy 1982, 12:145–149.
Lipton RB: Ergotamine tartrate and DHE-45 mesylate: safety profiles. Headache 1997, 37(suppl 1):S33-S41.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Swidan, S.Z., Lake, A.E. & Saper, J.R. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Current Science Inc 9, 65–70 (2005). https://doi.org/10.1007/s11916-005-0077-5
Issue Date:
DOI: https://doi.org/10.1007/s11916-005-0077-5